Skip to main

Roche to buy 89bio for up to $3.5b

18 Sep 2025

The company, which was founded in Israel, has a drug for treatment of fatty liver in phase III trials, which was initially an asset of Teva.


Read more:

Barron's: 89bio Stock Soars 86%. Why Roche Is Buying the Biopharma Company for $3.5 Billion

Wall Street Journal: Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion

Bloomberg: Roche to Buy 89bio for Up to $3.5 Billion in Obesity Push

Reuters: Roche to acquire liver drug developer 89bio for up to $3.5 billion


Category:
Sub Categories:
Share this article on social media
To read the full article, visit Globes websitehttps://en.globes.co.il/en/article-roche-to-buy-89bio-for-up-to-35b-1001522198 website
© All rights reserved to IVC and Israel Innovation Authority
Disclaimer:
The information provided on this platform is based solely on publicly available sources collected from the internet, including news articles, press releases, company websites, and other open-access materials.
The content is provided "AS IS" for informational purposes only and should not construed as professional, legal, or investment advice.
While we strive to ensure the accuracy and timeliness of the information presented, we do not guarantee its completeness or correctness.
Users are encouraged to independently verify any data before relying on it.
IVC shall bear no liability for investment decisions based on the information provided. In no event shall IVC or its employees, agents, or affiliates be liable for any direct, indirect, actual, special, or consequential damages resulting from the use of the information provided.